Malaria Pregnancy and Childbirth
Conditions
Interventions
Drug administration: Mefloquine (split dose)
Drug administration: Mefloquine (full dose)
Drug administration: Sulphadoxine-pyrimethamine
Sponsors
FCRB
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Permanent resident in the area Gestational age at the first antenatal visit < 28 weeks Signed informed consent Agreement to deliver in the study site's maternity wards
Exclusion criteria
Exclusion criteria: Residence outside the study area or planning to move out in the following 18 months from enrollment Gestational age at the first antenatal visit > 28 weeks of pregnancy Known history of allergy to sulfa drugs or mefloquine Known history of severe renal, hepatic, psychiatric or neurological disease MQ or halofantrine treatment in the preceding 4 weeks HIV infection Participating in other studies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of low borth weight (<2500 kg) | — |
Secondary
| Measure | Time frame |
|---|---|
| Prevalence of placental P. falciparum infection;Prevalence of moderate maternal anaemia at delivery;Prevalence of severe maternal anaemia at delivery;Mean maternal hemoglobin rate;Peripheral maternal parasitaemia ;Prevalence of P.falciparum in cord blood;Prevalence of fetal anaemia;Incidence of vomiting;Incidence of dizziness;Mean birth weight;Prevalence of prematurity;Number of stillbirths;Number of miscarriages;Mean gestational age;Incidence of clinical malaria;Incidence of overall admissiojns/outpatient attendances;Neonatal and infant mortality rate;Prevalence of congenital malaria;Incidence of malaria during the first year of life;Frequency of drug adverse reactions;Frequency of congenital malformations | — |
Countries
Benin, Gabon, Kenya, Mozambique, Tanzania
Contacts
Public ContactGolbahar Pahlavan
Project manager
Outcome results
None listed